Back to results
US 7,351,545 B2Granted
IGF binding proteins
AssigneeGenentech, Inc.
InventorsHenry Lowman, Samantha Lien
Life of this patent
Estimating the term…
Abstract
IGFBP-3 fusion proteins are provided that are useful, for example, in cell-based assays, as IGF antagonists, and in mapping IGF-I and IGF-II binding sites on other molecules such as wild-type IGFBP-3 and IGF agonist peptides identified by phage display. Methods for making such fusion proteins are also provided.
Claims4
A method for monitoring enhancement of apoptosis comprising pre-treating breast cancer cells with an IGFBP-3 fragment or fusion protein thereof that binds IGF-I or IGF-II for at least about 24 hours prior to treating the cells with an apoptotic factor and native-sequence human IGFBP-3 (SEQ ID NO:
- 1) or said IGFBP-3 fragment or fusion protein, and determining if the pre-treatment or treatment enhances the apoptosis induced by the treatment with the apoptotic factor.
Dependencies are inferred from the claim text.